Biblio

A. Din AEl, Thouant P., Guenancia C., Ricolfi F., Cochet A., Lorgis L., Zeller M., Bichat F., Baudoin N., Bejot Y. et al..  2018.  Cerebral microbleeds and acute coronary syndrome: screening and progression under dual anti-platelet therapy: proof of concept study. EUROPEAN HEART JOURNAL. 39:843.

Din AAlaa El, Debeaumarche H, Thouant P, Maza M, Ricolfi F, Zeller M, Bichat F, Baudouin N, Bejot Y, Cottin Y.  2020.  Cerebral microbleeds and acute myocardial infarction: Screening and disease progression. IJC HEART & VASCULATURE. 28:100531.

Carteron L, Bouzat P, Oddo M.  2017.  Cerebral Microdialysis Monitoring to improve individualized Neurointensive Care Therapy: An Update of Recent Clinical Data. FRONTIERS IN NEUROLOGY. 8:601.

de Sousa DAguiar, Ferro JM, Canhao P, Barinagarrementeria F, Bousser M-G, Stam J, Pinto ANogueira, Baptista MViana, Bejot Y, Dequatre-Ponchelle N et al..  2014.  Cerebral Venous Thrombosis Causing Posterior Fossa Lesions: Description of a Case Series and Assessment of Safety of Anticoagulation. CEREBROVASCULAR DISEASES. 38:384-388.

Couturier M-A, Huguet F, Chevallier P, Suarez F, Thomas X, Escoffre-Barbe M, Cacheux V, Pignon J-M, Bonmati C, Sanhes L et al..  2015.  Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience. AMERICAN JOURNAL OF HEMATOLOGY. 90:986-991.

Theiler M., Weibel L., Christen-Zaech S., Carmignac V., Sorlin A., Neuhaus K., Chevarin M., Thauvin-Robinet C., Philippe C., Faivre L. et al..  2021.  Cerebriform sebaceous nevus: a subtype of organoid nevus due to specific postzygotic FGFR2 mutations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 35:2085-2090.

Kuentz P., Theiler M., Carmignac V., Sorlin A., Vabres P..  2019.  Cerebriform sebaceous nevus is caused by the specific postzygotic FGRF2 p.(Cys382Arg) variation. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 139:S268.

Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MMuraine, Gabelle A, Lehmann S, Paquet C, Amar-Bouaziz E, Magnin E et al..  2018.  Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 89:467-475.

Marelli C, Hourregue C, Gutierrez L-A, Paquet C, de Champfleur NMenjot, De Verbizier D, Jacob M, Dubois J, Maleska AMaceski, Hirtz C et al..  2020.  Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late -Onset Behavioral Variants of Frontotemporal Dementia. JOURNAL OF ALZHEIMERS DISEASE. 74:903-911.

Taccone FS, Badenes R, Arib S, Rubulotta F, Mirek S, Franchi F, Gordon S, Nadji A, Crippa IA, Stazi E et al..  2020.  Cerebrospinal Fluid Glucose and Lactate Levels After Subarachnoid Hemorrhage: A Multicenter Retrospective Study. JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY. 32:170-176.

Chauzy A, Nadji A, Combes J-C, Defrance N, Bouhemad B, Couet W, Chavanet P.  2019.  Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 74:675-681.

Traenka C, Dougoud D, Simonetti BGoeggel, Metso TM, Debette S, Pezzini A, Kloss M, Grond-Ginsbach C, Majersik JJ, Worrall BB et al..  2017.  Cervical artery dissection in patients >= 60 years Often painless, few mechanical triggers. NEUROLOGY. 88:1313-1320.

Pivot X., Morere J-F., Couraud S., Touboul C., Blay J-Y., Cortot A.B, Lhomel C., Eisinger F., Greillier L., Viguier J..  2016.  Cervical cancer: Awareness and misconceptions of risk factors among lay persons and physicians. ANNALS OF ONCOLOGY. 27

Belglaiaa E, Mougin C.  2019.  Cervical cancer: Current situation and management in Morocco. BULLETIN DU CANCER. 106:1008-1022.

Grelat M, Gimenez C, Madkouri R.  2019.  Cervical Cord Compression by Exostosis. JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY. 49:112.

Pottecher P, Krause D, Di Marco L, Loffroy R, Estivalet L, Duhal R, Demondion X.  2015.  Cervical foraminal steroid injections under CT guidance: retrospective study of in situ contrast aspects in a serial of 248 cases. SKELETAL RADIOLOGY. 44:1-8.

Fahed E, Grelat M, Younes P, Madkouri R, Kreichati G, Kharrat K, Rizk T.  2019.  Cervical Hyperextension Deformity After Sagittal Balance Correction in Patient with Congenital Limb-Girdle Myopathy: Surgical Technique and Review of Literature. WORLD NEUROSURGERY. 123:265-271.

Troussier I, Bensadoun R-J, Chamorey E, Lapeyre M, Baujat B, Leysalle A, Sun XShan, Pointreau Y, Calugaru V, Pan Q et al..  2014.  Cervical node of unknown primary: Patterns of care and factors influencing the choice of clinical target volumes. ORAL ONCOLOGY. 50:E25-E26.

Espitalier F, de Keating-Hart A, Moriniere S, Badet J-M, Asseray N, Ferron C, Malard O.  2016.  Cervical spondylodiscitis following an invasive procedure on the neopharynx after circumferential pharyngolaryngectomy: a retrospective case series. EUROPEAN SPINE JOURNAL. 25:3894-3901.

Bouillet B, Gautier T., Terriat B., Lagrost L., Verges B., Petit J.M.  2019.  CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes. ACTA DIABETOLOGICA. 56:749-754.

Guigay J., Fayette J., Dillies A.F, Sire C., Kerger J.N, Tennevet I., Machiels J.P, Zanetta S., Pointreau Y., L. Le Moal B et al..  2015.  Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. ANNALS OF ONCOLOGY. 26:1941-1947.

Guiboux A.L, Zanetta S., Drouillard A., Grandvuillemin A..  2014.  Cetuximab infusion reactions: incidence and risk factors in 2 French medical centres. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 28:52.

Guiboux A.L, Zanetta S., Drouillard A., Grandvuillemin A..  2014.  Cetuximab infusion reactions: incidence and risk factors in 2 French medical centres. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 28:52.

Guigay J., Peyrade F., Petre-Lazar B., Mornex F., Ceruse P., Digue L., Berrier A., Degardin M., Alfonsi M., Artignan X. et al..  2014.  CETUXIMAB RELATIVE DOSE INTENSITY (RDI) IN RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): FIRST OBSERVATIONAL PROSPECTIVE STUDY IN UNSELECTED PATIENTS (DIRECT TRIAL). ANNALS OF ONCOLOGY. 25

Bourhis J, Sun XShan, Sire C, Tao Y, Martin L, Khoury C, Maingon P, Bardet E, Lapeyre M, Chatellier T et al..  2016.  Cetuximab-radiotherapy versus cetuximabradiotherapy plus concurrent chemotherapy in patients with NO-N2a squamous cell carcinoma of the head and neck ( SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.. JOURNAL OF CLINICAL ONCOLOGY. 34